With deep pockets, Solstice takes next-gen CTLA-4 into neoadjuvant treatment

Solstice’s $225 million series A will allow the NewCo to test whether administering its Fc-enhanced, shorter-acting CTLA-4 antibody before surgery can improve responses without toxicity delaying tumor removal.

Solstice Oncology Inc. made its formal debut Tuesday, seven months after the Asia-to-West NewCo emerged with ex-China rights to next-generation, Fc-enhanced anti-CTLA-4 mAb porustobart (HBM4003). Led by RA Capital Management, the series A closed at the time of the licensing deal, Solstice President and CEO Caroline Loew told BioCentury. Canaan Partners, Forbion, and undisclosed investors joined RA in the round...